16960-49-9

Basic information

• Product Name: N-[4-(1-oxopropyl)phenyl]acetamide
• Synonyms: N-[4-(1-oxopropyl)phenyl]acetamide;(4'-Propionyl)acetanilide;NSC 169084;p-Acetamidopropiophenone;AcetaMide, N-[4-(1-oxopropyl)phenyl]-
• CAS NO: 16960-49-9
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.22642
• EINECS: 241-032-7
• Mol File: 16960-49-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 172-173℃
• Boiling Point: 398℃
• Flash Point: 173℃
• Appearance: /
• Density: 1.121
• Vapor Pressure: 1.58E-06mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: 2-8°C
• PKA: 14.54±0.70(Predicted)
• CAS DataBase Reference: N-[4-(1-oxopropyl)phenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(1-oxopropyl)phenyl]acetamide(16960-49-9)
• EPA Substance Registry System: N-[4-(1-oxopropyl)phenyl]acetamide(16960-49-9)

Safety Data

• Hazardous Substances Data: 16960-49-9(Hazardous Substances Data)

Usage

General Description

N-[4-(1-oxopropyl)phenyl]acetamide is a chemical compound with the formula C11H13NO2. It is classified as an acetamide derivative and contains a phenyl group attached to an acetamide functional group. The presence of the 1-oxopropyl group suggests that it may have a ketone moiety in its structure. N-[4-(1-oxopropyl)phenyl]acetamide may be used in pharmaceutical and medicinal applications, as it has potential biological activities. Further research and experimentation are needed to explore the specific properties and potential uses of N-[4-(1-oxopropyl)phenyl]acetamide.

InChI:InChI=1/C11H13NO2/c1-3-11(14)9-4-6-10(7-5-9)12-8(2)13/h4-7H,3H2,1-2H3,(H,12,13)

Upstream product

• 79-03-8 propionyl chloride 
• 103-84-4 Acetanilid 
• 120-82-1 1,2,4-Trichlorobenzene 
• 79-05-0 Propionamid 
• 70-69-9 1-(4-aminophenyl)-1-propanone 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 20330-99-8 4-propylacetanilide 
• 70-69-9 1-(4-aminophenyl)-1-propanone 
• 15145-27-4 meso-3,4-bis-(4-amino-phenyl)-hexane 
• 97110-67-3 1-(4-acetylaminophenyl)-2-tert.-butylaminopropanone 
• 104657-22-9 (+/-)-2-(N-tert-butylamino)-4'-aminopropiophenone 
• 63514-63-6 N-(4-(2-bromopropionyl)phenyl)acetamide 
• 49660-99-3 N-(4-(3-(dimethylamino)-2-methylpropionyl)phenyl)acetamide 
• 216210-53-6 N-(4-(2-bromopropionyl)-2-nitrophenyl)acetamide 
• 60179-35-3 1-(3,4-diaminophenyl)propan-1-one 
• 31431-20-6 1-(4-amino-3-nitrophenyl)propan-1-one 
• 36725-28-7 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone 

Relevant articles and documents

Synthesis method of levosimendan drug intermediate p-acetaminophenylethylketone

The invention relates to a synthesis method of a levosimendan drug intermediate p-acetaminophenylethylketone, which comprises the following steps: adding 430-460ml of cyclohexane into a 1.5L reaction vessel which is provided with a stirrer, a reflux condenser and a thermometer, cooling the solution to 6-9 DEG C, slowly adding 2.9-3.1 mol of stannous chloride, refluxing for 80-120 minutes, and adding 1.0 mol of acetanilide in batches within 2-3 hours; after finishing addition, continuing reacting for 60-90 minutes, and adding 110ml of propanamide under reflux conditions within 3-4 hours; and after finishing addition, continuing refluxing for 5 hours until the solution becomes dark, distilling to remove the cyclohexane, heating the solution to 85-90 DEG C, reacting for 3-4 hours, adding the reaction product into 2.3L of oxalic acid solution, controlling the stirring rate at 160-190 rpm, precipitating a solid, filtering, washing the solid with a salt solution, washing with triethylamine, dehydrating with a dehydrating agent, and recrystallizing in propionitrile to obtain the p-acetaminophenylethylketone.

Synthesis and anti-congestive heart failure activity of novel levosimendan analogues

A series of levosimendan analogues were designed and synthesized, employing the Friedel-Crafts reaction, hydrolysis, and cyclization from the key intermediate compound R(-)-6-(4-aminophenyl)-5-methyl-4, 5-dihydro-3(2H)- pyridazinone, which was obtained from the starting material, acetanilide. These compounds, except 1b, exhibited potent anti-congestive heart failure activities, especially the compounds 1e and 1k, which showed more effective action than levosimendan. Springer Science+Business Media, LLC 2010.

NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

The present invention relates to novel benzimidazole-dihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, to processes for the preparation thereof and to the use thereof in therapy, especially for the treatment of diabetes.